Leadership Lessons is a monthly column from executives and thought leaders regarding best practices they use at their organizations to develop managers and leaders at all levels of the organization.
Your attention is your most valuable asset. Here’s how you can spend it wisely.
The fate of your business rests largely on the willingness of individuals to choose to invest their best discretionary effort in your company’s cause — to dig deep for innovative ideas, to imagine solutions outside any box, to perceive subtle shifts and faint signals.
“Superbosses” are known in their industries not merely for their innovation and financial success, but for spawning a generation of leaders.
Bigger might not be better when it comes to getting access to more diverse perspectives.
For 30 years I have been researching midsized, little-known global market leaders. I often observe five common traits in these leaders.
A big part of the innovation challenge for large pharma companies is that while researchers are very good at technical innovation, the business end is not.
It’s easy to say we value different perspectives. It is quite another thing to really mean it, especially when it comes to views that feel dangerous, unscientific, and just plain wrong.
Here’s what employers concerned about healthcare, and for that matter, productivity and employee retention, need to do.
For life science leaders who manage diverse teams, with members spanning geographic, disciplinary, and even organization boundaries, here are some powerful leadership practices that help improve innovation.
The next evolution of leadership may be navigating paradox, which means learning to adapt rather than managing paradox which finds a solution.
Why is it so difficult for leaders to discuss personal accountability? The closer it gets to the leaders of the company, the more it may be avoided.
Serial breakthrough innovators have some interesting commonalities that serve up some important lessons for how we can unleash the breakthrough innovation potential in us all. Here are three of them.
How do today’s healthcare executives stay focused on the right things, productive in the face of immense pressure and competing demands, and proactive and strategic in the way they lead? It all starts with taking a pause.
The pharmaceutical and healthcare industries are at a crossroads, with the traditional business models experiencing what some have described as “fatigue.” Like many other industries facing profound shifts, this creates the imperative to bring together the disparate fields of competitive strategy, innovation, and organizational change.
Dr. Helen Torley, president and CEO of Halozyme Therapeutics, shares a story of how the biopharmaceutical industry makes a difference.
Halozyme Therapeutics’ president and CEO, Dr. Helen Torley, discusses her path to the c-suite, including the formative experience that best prepared her for becoming a CEO.
Helen Torley, president and CEO of Halozyme Therapeutics, discusses hyaluronan and the role it plays in development of ENHANZE, PEGPH20 along with a staining diagnostic to determine patients with high levels of hyaluronic acid (HA).
Rob Wright provides insight into The Board Meeting West, a life sciences industry event for high-level biopharmaceutical executives serving on corporate boards, or hoping to do so in the near future.
Rob Wright provides a bit of his perspective on the 37th Annual J.P. Morgan Healthcare Conference.